Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cell Simulation as Cell Segmentation.

bioRxiv : the preprint server for biology·2024

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 10, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Integrating Three Functional Subsets of T Cell Immunity Into an Integrative Model for Cancer Immunotherapy.

Jaeyoun Park^1,2, Heeju Ryu^1,2

¹Department of Immunology, School of Medicine, Sungkyunkwan University, Suwon 16419, Korea.

|March 9, 2026

Summary

Cancer immunotherapy can be improved by understanding T cell subsets. Virus-specific T cells (VSTs) and bystander T cells play key roles alongside tumor-specific T cells (TASTs), offering new therapeutic strategies.

Keywords:

Adoptive cell therapy Bystander T cells Cancer immunotherapy Immune checkpoint inhibitors Tumor Ag-specific T cells Virus-specific T cells

More Related Videos

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Related Experiment Videos

Last Updated: Mar 10, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Area of Science:

Immunology
Oncology
Cellular Biology

Background:

Current cancer immunotherapy primarily uses tumor-antigen specific T cells (TASTs).
Checkpoint blockade therapy, while effective, faces limitations due to issues like T cell exhaustion and inefficient priming.
Tumor microenvironments are complex, often containing more virus-specific T cells (VSTs) and bystander T cells than TASTs.

Purpose of the Study:

To propose an integrative model of T cell subsets within the tumor microenvironment.
To characterize these subsets based on their origin and gene expression.
To explore their potential as biomarkers and therapeutic targets in cancer immunotherapy.

Main Methods:

Analysis of high-dimensional single-cell data.
Characterization of T cell subsets by ontogeny and transcriptional programs.
Development of an integrative model for T cell function in tumors.

Main Results:

Identified three functional T cell subsets: classical TASTs, VSTs with potential TAST function, and bystander T cells.
Demonstrated that VSTs can act as TASTs through viral mimicry.
Highlighted the heterogeneity of the tumor immune ecosystem.

Conclusions:

These T cell subsets can serve as predictive biomarkers for immunotherapy response.
Distinct therapeutic strategies, including adoptive cell transfer, can be developed for each subset.
This model aids in understanding resistance in cold tumors and guides novel treatment approaches.